2021 Revenues ($USD) : $18,471,000,000
2021 R&D spend : $1,991,000,000
2021 Number of Employees : 2,700
Fiscal Year End : 12/31/2021
Leader : CEO Stéphane Bancel

A newcomer to pharma’s upper echelon, Moderna presently has a single commercialized product — its COVID-19 vaccine. That said, with $17.7 billion in sales, its Spikevax helped fuel pipeline progress. In March 2022, the company predicted its Spikevax vaccine would generate $21 billion in annual sales. Moderna is also working to develop vaccines to target a variety of next-gen COVID-19 vaccines. The company now has more than 40 product candidates in development. —BB